Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Xiaoyu Zhu, ph.D
- Phone Number: 15255456091
- Email: xiaoyuz@ustc.edu.cn
Study Contact Backup
- Name: Kaidi Song, M.D
- Phone Number: 18715062778
- Email: kaidisong@163.com
Study Locations
-
-
-
Hefei, China
- The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
-
Contact:
- Xiaoyu Zhu, ph.D
- Phone Number: 15255456091
- Email: xiaoyuz@ustc.cn
-
Contact:
- Kaidi Song, M.D
- Phone Number: 18715062778
- Email: kaidisong@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Malignant hematologic disorders;
- Patients undergoing UCBT;
- Female patients of childbearing potential must have a negative pregnancy test and agree to use effective contraception during treatment and for the following year.
Exclusion Criteria:
- Non-malignant hematologic disorders;
- History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
- Uncontrolled bacterial, viral, or fungal infections. "Uncontrolled" is defined as lack of clinical improvement or progression despite adequate antimicrobial therapy;
- HIV infection or active hepatitis B or C virus infection;
- Pregnant or lactating women;
- Substance abusers; subjects with uncontrolled psychiatric disorders; individuals with cognitive dysfunction;
- Participation in similar clinical studies within the past 3 months;
- Subjects deemed unsuitable by the investigator (e.g., those expected to be unable to adhere to treatment due to financial constraints).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: basiliximab group
|
Addition of CD25 monoclonal antibody(Basiliximab) at +3 days post unrelated umbilical cord blood transplantation (UCBT)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The cumulative incidence of grade III-IV acute graft-versus-host disease (aGVHD)
Time Frame: within 100 days post-UCBT
|
The primary endpoint of the study will be the development of aGVHD in the first 100 days post-transplant.
Acute GVHD was graded according to the International Consortium criteria.
|
within 100 days post-UCBT
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The cumulative incidence of transplant-related mortality at 180 days after transplantation
Time Frame: 180 days
|
The cumulative incidence of transplant-related mortality at 180 days after transplantation.
|
180 days
|
|
The cumulative incidence of chronic GVHD at 360 days after transplantation
Time Frame: 360 days
|
The severity of chronic GVHD was graded according to the 2014 NIH criteria.
|
360 days
|
|
The incidence rate and occurrence time of pre-engraftment syndrome (PES)
Time Frame: within 30 days post-UCBT
|
The occurrence time and cumulative incidence of PES within 30 days post-UCBT.
The PES was diagnosed according to the criteria of engraftment syndrome (ES) .
|
within 30 days post-UCBT
|
|
The cumulative incidence of neutrophil engraftment at 28 days after transplantation
Time Frame: within 28 days post-UCBT
|
Neutrophil engraftment time was defined as the first of three consecutive days during which the neutrophil count was at least 0.5×10^9/L.
|
within 28 days post-UCBT
|
|
The cumulative incidence of platelet engraftment at 100 days after transplantation
Time Frame: within 100 days post-UCBT
|
Platelet engraftment is defined as independence from platelet transfusion for at least 7 days with a platelet count of more than ≥ 20 × 10^9/L.
|
within 100 days post-UCBT
|
|
The incidence of grade II to IV aGVHD
Time Frame: within 100 days post-UCBT
|
The cumulative incidence of grade II to IV aGVHD in the first 100 days post-transplant.
aGVHD was graded according to the aGVHD International Consortium criteria.
|
within 100 days post-UCBT
|
|
The cumulative incidence of relapse
Time Frame: 1 year
|
The cumulative incidence of relapse at 1 year after transplantation.
|
1 year
|
|
The probability of disease-free survival(DFS)
Time Frame: 1 year
|
The DFS was defined as the interval between transplantation and disease recurrence, death or the last follow-up date, whichever occurred first.
|
1 year
|
|
The probability of overall survival(OS)
Time Frame: 1 year
|
The OS was determined to be the time from the first day of transplantation until death from any cause or the last follow-up date.
|
1 year
|
|
The probability of GVHD-free, relapse-free survival(GRFS)
Time Frame: 1 year
|
The composite endpoint of GRFS was defined as the first events occurring after transplantation among Grade III to IV aGVHD, moderate to severe cGVHD, relapse, or death for any reason.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Xiaoyu Zhu, ph.D, The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CD25-2024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.